WHAT ARE YOU 2024 TONIGHT ON ABC? >> SO WE ARE BACK NOW WITH THE NEW RESEARCH THAT'S BRINGING NEW HOPE FOR BREAST CANCER NEW HOPE FOR BREAST CANCER PATIENTS. PATIENTS. >> DEAD INDICATES A DRUG THAT'S >> DEAD INDICATES A DRUG THAT'S ALREADY ON THE MARKET COULD ALREADY ON THE MARKET COULD DRAMATICALLY REDUCE THE RISK OF DRAMATICALLY REDUCE THE RISK OF RECURRENCE OF BREAST CANCER. RECURRENCE OF BREAST CANCER. ABC NEWS EVA PILGRIM HAS ABC NEWS EVA PILGRIM HAS THE LATEST EXCITING NEWS FOR THE LATEST EXCITING NEWS FOR THOSE DIAGNOSED WITH EARLY THOSE DIAGNOSED WITH EARLY STAGE BREAST CANCER. STAGE BREAST CANCER. >> REID AND RELAX. >> REID AND RELAX. >> NEW RESEARCH REVEALS >> NEW RESEARCH REVEALS THE DRUG RIBEAU CYCLIC MARKETED THE DRUG RIBEAU CYCLIC MARKETED UNDER THE NAME CHRIS CONNELLY, UNDER THE NAME CHRIS CONNELLY, CAN LOWER THE CHANCES OF CAN LOWER THE CHANCES OF RECURRENCE FOR MANY OF THOSE RECURRENCE FOR MANY OF THOSE DIAGNOSED AT EARLIER STAGES OF DIAGNOSED AT EARLIER STAGES OF THE DISEASE. THE DISEASE. WOMEN WHO ARE HORMONE RECEPTOR WOMEN WHO ARE HORMONE RECEPTOR POSITIVE AND HER TO NEGATIVE POSITIVE AND HER TO NEGATIVE MAKE UP 70% OF THE CANCER MAKE UP 70% OF THE CANCER POPULATION. POPULATION. THESE PATIENTS ARE GENERALLY THESE PATIENTS ARE GENERALLY TREATED WITH CHEMOTHERAPY TREATED WITH CHEMOTHERAPY AND ENDOCRINE THERAPY, BUT AND ENDOCRINE THERAPY, BUT THE STUDY SHOWS ADDING THIS THE STUDY SHOWS ADDING THIS TARGETED THERAPY WILL FURTHER TARGETED THERAPY WILL FURTHER REDUCE THE RISK THAT THE CANCER REDUCE THE RISK THAT THE CANCER RETURNS. RETURNS. >> WOMEN WHO HAVE THIS SUBTYPE >> WOMEN WHO HAVE THIS SUBTYPE CAN HAVE RECURRENCES. CAN HAVE RECURRENCES. EVEN TWENTY TO EVEN TWENTY TO TWENTY FIVE YEARS AFTER TWENTY FIVE YEARS AFTER THEIR INITIAL DIAGNOSIS, WE THEIR INITIAL DIAGNOSIS, WE FOUND THAT ADDING THIS DRUG FOUND THAT ADDING THIS DRUG TO BEST AVAILABLE STANDARD TO BEST AVAILABLE STANDARD THERAPY WILL DECREASE THERAPY WILL DECREASE THE RECURRENCE RATE BY AS MUCH THE RECURRENCE RATE BY AS MUCH AS TWENTY FIVE PERCENT. AS TWENTY FIVE PERCENT. THIS IS BIG NEWS FOR PATIENTS THIS IS BIG NEWS FOR PATIENTS LIKE 45 YEAR OLD MOM SUZANNE LIKE 45 YEAR OLD MOM SUZANNE GARDNER, DIAGNOSED WITH STAGE GARDNER, DIAGNOSED WITH STAGE TWO FIVE YEARS AGO. TWO FIVE YEARS AGO. DOCTORS TREATED WITH CHEMO DOCTORS TREATED WITH CHEMO AND ENDOCRINE THERAPY. AND ENDOCRINE THERAPY. >> I DIDN'T FEEL GREAT. >> I DIDN'T FEEL GREAT. >> I FELT THAT MY RISK OF >> I FELT THAT MY RISK OF RECURRENCE WAS STILL TOO HIGH. RECURRENCE WAS STILL TOO HIGH. THEN SHE FOUND THEN SHE FOUND THE CHRIS CONNELLY CLINICAL THE CHRIS CONNELLY CLINICAL TRIAL. TRIAL. >> I HAVE A YOUNG DAUGHTER >> I HAVE A YOUNG DAUGHTER WHO NEEDS HER MOM AROUND FOR WHO NEEDS HER MOM AROUND FOR AS LONG AS POSSIBLE, AND I AS LONG AS POSSIBLE, AND I WOULD ABSOLUTELY DO ANYTHING WOULD ABSOLUTELY DO ANYTHING TO REDUCE MY RISK OF RECURRENCE TO REDUCE MY RISK OF RECURRENCE SO I CAN BE HER MOM FOR AS LONG SO I CAN BE HER MOM FOR AS LONG AS SHE NEEDS. AS SHE NEEDS. >> ALL RIGHT. >> ALL RIGHT. THANKS TO EVA FOR THAT. THANKS TO EVA FOR THAT. FOR MORE , LET'S BRING IN FOR MORE , LET'S BRING IN ABC NEWS CONTRIBUTOR ABC NEWS CONTRIBUTOR AND EMERGENCY PHYSICIAN DR. AND EMERGENCY PHYSICIAN DR. DARIAN . DARIAN . GOOD TO SEE YOU . GOOD TO SEE YOU . THIS IS GREAT NEWS. THIS IS GREAT NEWS. HOW MANY MORE CANCER PATIENTS HOW MANY MORE CANCER PATIENTS DO YOU THINK WILL THIS DO YOU THINK WILL THIS TREATMENT NOW BE OPEN TO ? TREATMENT NOW BE OPEN TO ? >> AND WHAT KINDS OF PATIENTS >> AND WHAT KINDS OF PATIENTS ARE ELIGIBLE FOR? ARE ELIGIBLE FOR? >> THIS IS INCREDIBLE NEWS >> THIS IS INCREDIBLE NEWS AND IT SPECIFICALLY FOR AND IT SPECIFICALLY FOR A SPECIFIC TYPE OF CANCER, A SPECIFIC TYPE OF CANCER, AS WAS JUST STATED, HORMONE AS WAS JUST STATED, HORMONE POSITIVE. POSITIVE. HER TWO NEGATIVE BREAST CANCER HER TWO NEGATIVE BREAST CANCER ,WHICH IS ACTUALLY THE MOST ,WHICH IS ACTUALLY THE MOST COMMON FORM OF BREAST CANCER COMMON FORM OF BREAST CANCER EACH YEAR. EACH YEAR. THERE'S APPROXIMATELY THERE'S APPROXIMATELY TWO HUNDRED AND FIFTY THOUSAND TWO HUNDRED AND FIFTY THOUSAND NEW CASES OF BREAST CANCER. NEW CASES OF BREAST CANCER. AND THIS TYPE ACCOUNTS FOR AND THIS TYPE ACCOUNTS FOR APPROXIMATELY 70%. APPROXIMATELY 70%. SO THIS NEW CLINICAL TRIAL SO THIS NEW CLINICAL TRIAL AND THIS RESEARCH IS BOUND AND THIS RESEARCH IS BOUND TO HELP HUNDREDS OF THOUSANDS, TO HELP HUNDREDS OF THOUSANDS, MAYBE EVEN MORE PATIENTS MAYBE EVEN MORE PATIENTS WHO ARE SUFFERING FROM THIS WHO ARE SUFFERING FROM THIS DIAGNOSIS AND GIVING THEM A NEW DIAGNOSIS AND GIVING THEM A NEW A NEW ERA OF HOPE. A NEW ERA OF HOPE. >> HMM. >> HMM. SO HOW BIG OF A CONCERN SO HOW BIG OF A CONCERN IS CANCER RECURRENCE FOR IS CANCER RECURRENCE FOR PATIENTS WITH EARLY STAGE PATIENTS WITH EARLY STAGE BREAST CANCER? BREAST CANCER? WELL, I THINK THAT CANCER WELL, I THINK THAT CANCER RECURRENCE IS ALWAYS IN RECURRENCE IS ALWAYS IN THE BACK OF THE MIND OF ANYONE THE BACK OF THE MIND OF ANYONE SUFFERING FROM CANCER SUFFERING FROM CANCER AND THRIVING AND LIVING THROUGH AND THRIVING AND LIVING THROUGH THEIR CANCER DIAGNOSIS. THEIR CANCER DIAGNOSIS. MORE SPECIFICALLY WITH THIS MORE SPECIFICALLY WITH THIS TYPE OF CANCER, THOSE WHO ARE TYPE OF CANCER, THOSE WHO ARE DIAGNOSED WITH STAGE TWO DIAGNOSED WITH STAGE TWO CANCER, THIS IS HORMONE CANCER, THIS IS HORMONE POSITIVE. POSITIVE. HER TWO NEGATIVE, APPROXIMATELY HER TWO NEGATIVE, APPROXIMATELY 30% WILL HAVE A RISK OF 30% WILL HAVE A RISK OF RECURRENCE AND THAT RECURRENCE RECURRENCE AND THAT RECURRENCE CAN OCCUR AT ANY POINT IN CAN OCCUR AT ANY POINT IN THEIR LIFETIME. THEIR LIFETIME. AND THEN IF YOU'RE DIAGNOSED AND THEN IF YOU'RE DIAGNOSED WITH LATER STAGE STAGE THREE , WITH LATER STAGE STAGE THREE , APPROXIMATELY 50% OF PATIENTS APPROXIMATELY 50% OF PATIENTS WHO ARE DIAGNOSED WITH THAT WHO ARE DIAGNOSED WITH THAT GET A RECURRENCE AT SOME POINT GET A RECURRENCE AT SOME POINT IN THEIR LIFETIME. IN THEIR LIFETIME. NOW, THIS MEDICATION HAS BEEN NOW, THIS MEDICATION HAS BEEN SHOWN AT ITS BEST TO REDUCE SHOWN AT ITS BEST TO REDUCE THAT RISK OF RECURRENCE BY MORE THAT RISK OF RECURRENCE BY MORE THAN 25%. THAN 25%. >> SO THAT'S MONUMENTAL. >> SO THAT'S MONUMENTAL. AND WHERE IS THIS TREATMENT FIT AND WHERE IS THIS TREATMENT FIT IN THE BROADER FIGHT AGAINST IN THE BROADER FIGHT AGAINST BREAST CANCER? BREAST CANCER? HOW HOW WELL ARE WE DOING IN HOW HOW WELL ARE WE DOING IN TERMS OF RESEARCH TERMS OF RESEARCH AND TREATMENTS? AND TREATMENTS? AND I GUESS WHAT IS STILL AND I GUESS WHAT IS STILL THE MOST COMMON CANCER AMONG THE MOST COMMON CANCER AMONG WOMEN, RIGHT? WOMEN, RIGHT? >> ABSOLUTELY. >> ABSOLUTELY. EVERY SINGLE DAY THERE'S EVERY SINGLE DAY THERE'S MORE RESEARCH, MORE DATA, MORE RESEARCH, MORE DATA, MORE INTERVENTIONS THAT CAN MORE INTERVENTIONS THAT CAN HELP MORE PEOPLE. HELP MORE PEOPLE. THIS MEDICATION IS GOING TO BE THIS MEDICATION IS GOING TO BE SEEN AS AN ADDITIVE TO WHAT WE SEEN AS AN ADDITIVE TO WHAT WE ALREADY TO BE HELPFUL ALREADY TO BE HELPFUL AND EFFECTIVE AS FAR AS WHAT AND EFFECTIVE AS FAR AS WHAT WAS JUST STATED, THINGS LIKE WAS JUST STATED, THINGS LIKE CHEMOTHERAPY, HORMONE THERAPY. CHEMOTHERAPY, HORMONE THERAPY. THIS SPECIFIC MEDICATION WORKS THIS SPECIFIC MEDICATION WORKS BY BLOCKING THOSE CANCER CELLS BY BLOCKING THOSE CANCER CELLS AND DOESN'T ALLOW THEM AND DOESN'T ALLOW THEM TO MULTIPLY. TO MULTIPLY. IT IS IMPORTANT, HOWEVER, IT IS IMPORTANT, HOWEVER, TO UNDERSTAND THE SIDE EFFECTS. TO UNDERSTAND THE SIDE EFFECTS. MOST COMMONLY NOTED ARE NAUSEA, MOST COMMONLY NOTED ARE NAUSEA, VOMITING, HEADACHE AND ALSO IT VOMITING, HEADACHE AND ALSO IT CAN DECREASE YOUR WHITE CAN DECREASE YOUR WHITE BLOOD CELLS, WHICH ARE REALLY BLOOD CELLS, WHICH ARE REALLY IMPORTANT TO HELP YOU TO FIGHT IMPORTANT TO HELP YOU TO FIGHT INFECTION. INFECTION. SO THAT'S IMPORTANT SO THAT'S IMPORTANT TO UNDERSTAND FOR SURVEILLANCE TO UNDERSTAND FOR SURVEILLANCE OR MONITORING. OR MONITORING. OF COURSE, MAKE SURE THAT WE OF COURSE, MAKE SURE THAT WE HAVE THE HIGHEST LEVEL OF HAVE THE HIGHEST LEVEL OF